While the findings are promising, the authors emphasized that tart cherry juice should not be viewed as a standalone treatment. Instead, its value lies in its role as an adjunctive intervention that may enhance disease control when combined with standard therapy. Larger and longer-term trials will be necessary to confirm durability of the effect, determine optimal dosing, and assess whether benefits extend to patients with more severe disease.
In conclusion, the 2025 randomized, placebo-controlled trial published by researchers from the University of Hertfordshire and the University of Central Lancashire provides strong evidence that Montmorency tart cherry juice can significantly reduce intestinal inflammation and improve quality of life in adults with mild-to-moderate ulcerative colitis (npj Science of Food, 2025). These findings support the growing recognition that targeted dietary strategies rich in bioactive compounds may play an important complementary role in the long-term management of inflammatory bowel disease.
ADVERTISEMENT
